bioMérieux S.A. (LON:0RUG)

London flag London · Delayed Price · Currency is GBP · Price in EUR
74.03
+1.08 (1.49%)
At close: May 13, 2026
Market Cap7.56B -36.7%
Revenue (ttm)3.55B +2.3%
Net Income346.77M -8.0%
EPS2.91 -8.2%
Shares Outn/a
PE Ratio21.79
Forward PE16.35
Dividend0.76 (1.04%)
Ex-Dividend DateJun 9, 2025
Volume11,512
Average Volume80,795
Open73.35
Previous Close72.94
Day's Range73.35 - 75.20
52-Week Range68.05 - 128.40
Beta0.54
RSI30.53
Earnings DateJul 28, 2026

About bioMérieux

bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; BACT/ALERT VIRTUO, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system (PCR); BIOFIRE SPOTFIRE, a lowplex PCR point-of... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 1963
Employees 14,894
Stock Exchange London Stock Exchange
Ticker Symbol 0RUG

Financial Performance

In 2025, bioMérieux's revenue was 4.07 billion, an increase of 2.26% compared to the previous year's 3.98 billion. Earnings were 397.50 million, a decrease of -8.03%.

Financial numbers in EUR Financial Statements